C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) – Stock analysts at Brookline Capital Markets lifted their Q3 2026 earnings estimates for C4 Therapeutics in a research report issued on Tuesday, August 11th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings per share of ($0.20) for the quarter, up from their previous forecast of ($0.21). The consensus estimate for C4 Therapeutics’ current full-year earnings is ($0.87) per share. Brookline Capital Markets also issued estimates for C4 Therapeutics’ FY2026 earnings at ($0.80) EPS, FY2027 earnings at ($0.93) EPS and FY2028 earnings at ($1.64) EPS.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. C4 Therapeutics had a negative return on equity of 47.15% and a negative net margin of 289.44%.The firm had revenue of $6.64 million during the quarter, compared to analyst estimates of $4.00 million.
Check Out Our Latest Stock Analysis on C4 Therapeutics
C4 Therapeutics Trading Up 0.8%
CCCC opened at $3.90 on Thursday. The company has a market cap of $431.22 million, a price-to-earnings ratio of -3.90 and a beta of 2.91. The stock has a fifty day simple moving average of $3.90 and a two-hundred day simple moving average of $3.17. C4 Therapeutics has a 12-month low of $1.69 and a 12-month high of $5.17.
Institutional Trading of C4 Therapeutics
A number of institutional investors have recently made changes to their positions in CCCC. AQR Capital Management LLC boosted its stake in shares of C4 Therapeutics by 957.6% in the 1st quarter. AQR Capital Management LLC now owns 140,532 shares of the company’s stock worth $225,000 after buying an additional 127,244 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of C4 Therapeutics by 8.6% in the first quarter. Goldman Sachs Group Inc. now owns 622,720 shares of the company’s stock worth $996,000 after acquiring an additional 49,065 shares during the period. Acadian Asset Management LLC purchased a new stake in C4 Therapeutics during the first quarter valued at $43,000. XTX Topco Ltd lifted its holdings in C4 Therapeutics by 170.0% in the second quarter. XTX Topco Ltd now owns 108,278 shares of the company’s stock valued at $155,000 after acquiring an additional 68,178 shares during the period. Finally, Invesco Ltd. boosted its position in C4 Therapeutics by 11.1% in the second quarter. Invesco Ltd. now owns 155,017 shares of the company’s stock worth $222,000 after purchasing an additional 15,531 shares during the last quarter. Hedge funds and other institutional investors own 78.81% of the company’s stock.
About C4 Therapeutics
C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.
The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.
Read More
- Five stocks we like better than C4 Therapeutics
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
